These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 1651710)
21. Silver-resistant mutants of Escherichia coli display active efflux of Ag+ and are deficient in porins. Li XZ; Nikaido H; Williams KE J Bacteriol; 1997 Oct; 179(19):6127-32. PubMed ID: 9324262 [TBL] [Abstract][Full Text] [Related]
22. [Antibacterial activities of ofloxacin against recent isolates from patients with community-acquired infections]. Deguchi K; Yokota N; Koguchi M; Nakane Y; Suzuki Y; Fukayama S; Ishihara R; Oda S Jpn J Antibiot; 1991 Sep; 44(9):941-57. PubMed ID: 1960856 [TBL] [Abstract][Full Text] [Related]
23. Enhanced bacterial uptake and bactericidal properties of ofloxacin loaded on bioadhesive hydrogels against Pseudomonas aeruginosa. Romero VL; Manzo RH; Alovero FL J Chemother; 2010 Oct; 22(5):328-34. PubMed ID: 21123156 [TBL] [Abstract][Full Text] [Related]
24. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Lomovskaya O; Warren MS; Lee A; Galazzo J; Fronko R; Lee M; Blais J; Cho D; Chamberland S; Renau T; Leger R; Hecker S; Watkins W; Hoshino K; Ishida H; Lee VJ Antimicrob Agents Chemother; 2001 Jan; 45(1):105-16. PubMed ID: 11120952 [TBL] [Abstract][Full Text] [Related]
25. Contributions of IMP-10 metallo-beta-lactamase, the outer membrane barrier and the MexAB-OprM efflux system to high-level carbapenem resistance in Pseudomonas aeruginosa. Zhao WH; Hu Z; Chen G; Ito R; Hu ZQ Chemotherapy; 2009; 55(3):168-74. PubMed ID: 19420932 [TBL] [Abstract][Full Text] [Related]
26. RELATIVE EXPRESSION OF EFFLUX PUMPS IN MULTI DRUG RESISTANT PSEUDOMONAS AERUGINOSA. Azimi L; Namvar AE; Jamali S; Lari AR; Bijari A; Lari AR Roum Arch Microbiol Immunol; 2015; 74(3-4):86-90. PubMed ID: 27328522 [TBL] [Abstract][Full Text] [Related]
27. Factors influencing the accumulation of ciprofloxacin in Pseudomonas aeruginosa. Celesk RA; Robillard NJ Antimicrob Agents Chemother; 1989 Nov; 33(11):1921-6. PubMed ID: 2514623 [TBL] [Abstract][Full Text] [Related]
29. The action of Pseudomonas aeruginosa biofilms in intrinsic drug resistance. Xie Y; Jia WX; Zeng W; Yang WQ; Cheng X; Li XR; Wang LL; Kang M; Zhang ZR Chin Med J (Engl); 2005 Oct; 118(19):1615-22. PubMed ID: 16232346 [TBL] [Abstract][Full Text] [Related]
30. [In vitro activity of seven gyrase inhibitors of a group of heterocyclic carbonic acids against nonfermenting gram negative rods (nonfermenters)]. Grimm H Arzneimittelforschung; 1985; 35(3):570-2. PubMed ID: 2986655 [TBL] [Abstract][Full Text] [Related]
31. Emergence of multidrug-resistant mutants is increased under antibiotic selective pressure in Pseudomonas aeruginosa. Alonso A; Campanario E; Martínez JL Microbiology (Reading); 1999 Oct; 145 ( Pt 10)():2857-62. PubMed ID: 10537207 [TBL] [Abstract][Full Text] [Related]
32. Cross-resistance between triclosan and antibiotics in Pseudomonas aeruginosa is mediated by multidrug efflux pumps: exposure of a susceptible mutant strain to triclosan selects nfxB mutants overexpressing MexCD-OprJ. Chuanchuen R; Beinlich K; Hoang TT; Becher A; Karkhoff-Schweizer RR; Schweizer HP Antimicrob Agents Chemother; 2001 Feb; 45(2):428-32. PubMed ID: 11158736 [TBL] [Abstract][Full Text] [Related]
33. [Serotypes and drug susceptibility of Pseudomonas aeruginosa isolated from clinical specimens]. Nakae M; Sugahara Y; Sasaki H; Yasui H; Imai C; Hasegawa Y; Osaka K; Shibasaki K Jpn J Antibiot; 1997 Feb; 50(2):187-94. PubMed ID: 9100078 [TBL] [Abstract][Full Text] [Related]
34. Evidence that a novel quaternary compound and its organic N-chloramine derivative do not select for resistant mutants of Pseudomonas aeruginosa. De Silva M; Ning C; Ghanbar S; Zhanel G; Logsetty S; Liu S; Kumar A J Hosp Infect; 2015 Sep; 91(1):53-8. PubMed ID: 26122622 [TBL] [Abstract][Full Text] [Related]
35. Reduction of the fitness burden of quinolone resistance in Pseudomonas aeruginosa. Kugelberg E; Löfmark S; Wretlind B; Andersson DI J Antimicrob Chemother; 2005 Jan; 55(1):22-30. PubMed ID: 15574475 [TBL] [Abstract][Full Text] [Related]
36. New norfloxacin resistance gene in Pseudomonas aeruginosa PAO. Fukuda H; Hosaka M; Hirai K; Iyobe S Antimicrob Agents Chemother; 1990 Sep; 34(9):1757-61. PubMed ID: 2126688 [TBL] [Abstract][Full Text] [Related]
37. Characterization of fluoroquinolone and carbapenem susceptibilities in clinical isolates of levofloxacin-resistant Pseudomonas aeruginosa. Muramatsu H; Horii T; Takeshita A; Hashimoto H; Maekawa M Chemotherapy; 2005 May; 51(2-3):70-5. PubMed ID: 15870499 [TBL] [Abstract][Full Text] [Related]
38. [Interpretive reading of the non-fermenting gram-negative bacilli antibiogram]. Vila J; Marco F Enferm Infecc Microbiol Clin; 2010 Dec; 28(10):726-36. PubMed ID: 20579775 [TBL] [Abstract][Full Text] [Related]
39. Contribution of the MexAB-OprM multidrug efflux system to the beta-lactam resistance of penicillin-binding protein and beta-lactamase-derepressed mutants of Pseudomonas aeruginosa. Srikumar R; Tsang E; Poole K J Antimicrob Chemother; 1999 Oct; 44(4):537-40. PubMed ID: 10588316 [TBL] [Abstract][Full Text] [Related]
40. Mechanisms of quinolone resistance in clinical isolates: accumulation of sparfloxacin and of fluoroquinolones of various hydrophobicity, and analysis of membrane composition. Denis A; Moreau NJ J Antimicrob Chemother; 1993 Sep; 32(3):379-92. PubMed ID: 8262860 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]